Article Text

Download PDFPDF
Relief of obstructive jaundice from pancreatic cancer: the end of the plastic stent era?
  1. Todd H Baron,
  2. Ian S Grimm
  1. Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA
  1. Correspondence to Professor Todd H Baron, Division of Gastroenterology and Hepatology, University of North Carolina, 130 Mason Farm Road, CB 7080, Chapel Hill, NC 27599, USA; todd_baron{at}med.unc.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Initially described by Soehendra and Reynders-Frederix1 in 1980, plastic stents have been widely used for endoscopic relief of malignant biliary obstruction. The relative ease of placement and removal of plastic stents, as well as their low cost, have made them an attractive option for the past 35 years. It has been apparent for decades, however, that self-expandable metal stents (SEMS) provide much more durable biliary drainage than plastic stents. Accumulating evidence now suggests that it may no longer be justifiable to use plastic stents when it is clear that metal stents are associated with superior outcomes, fewer adverse events (AEs) and fewer repeated interventions.2 These advantages, along with reductions in length of hospital stay, appear to fully offset the high initial cost of selecting an SEMS over a plastic stent for palliation of malignant distal biliary obstruction—even in patients whose projected life expectancy is limited.3 ,4 In patients with borderline resectable pancreatic cancer who are undergoing neoadjuvant therapy, SEMS have also …

View Full Text

Footnotes

  • Contributors Both authors contributed equally.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.